Nationwide chain of mental health centers accused of unlawfully imprisoning patients

A nationwide chain of for-profit mental health centers is alleged to be holding patients against their will without medical justification to milk insurance payouts, a report from the New York Times said. 

Acadia Healthcare is a publicly traded company, operating behavioral health clinics in 19 states. According to the Times, in 12 of those states, patients, employees and law enforcement have filed complaints against Acadia for unethically and illegally detaining people, accusing leadership of abusing laws meant for individuals who pose an immediate threat to themselves or others. 

In response, the company has called the claims inaccurate and disputes the characterization. 

However, the Times cited multiple sources and specific examples where Acadia exaggerated patients’ symptoms, lied about their health and allegedly tweaked medication dosages to prolong inpatient stays. The company would routinely hold patients until their insurance ran out, reporters said. 

In some cases, families would hire lawyers and file legal action to get their loved ones released. In interviews with the outlet, former employees said Acadia had strategies it deployed to get insurance companies to keep paying while patients were being held for dubious reasons. 

Read the full feature from the New York Times at the link below. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.